secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2022-05-17T23:59:59+00:00
Accession:  0001104659-22-061599
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.03, 2.01, 3.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea completes acquisition of Atrin; appoints Oren Gilad as CEO, new directors
-------------------------------------------------------------------------------

- Issued 1,117,394 common shares and 2,949,630 Series A Preferred (each convertible into 10 common) to Atrin securityholders.
- Certain stockholders agreed to 180-day lock-up on sale of shares received in merger.
- CVRs entitle Aprea legacy holders to cash from disposition of mutant p53 assets within 2 years.
- Oren Gilad appointed President, to become CEO; Christian Schade to stay as Executive Chairman for 6 months.
- Aprea notified Nasdaq of audit committee vacancy due to director resignation; intends to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/0001104659-22-061599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-061599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer